Prula-cel Extends the Allogeneic CAR-T Autoimmune Thesis

Company Adicet Bio Event Type Phase 1 Results Modality Allogeneic Gamma-Delta CAR-T Asset Prulacabtagene Leucel (Prula-cel) Target CD20 Disease Area Systemic Lupus Erythematosus; Lupus Nephritis Summary Adicet reported Phase 1 data for prulacabtagene leucel, an allogeneic gamma-delta anti-CD20 CAR-T therapy, in systemic lupus erythematosus with…